Type I Interferon Potentiates IgA Immunity to Respiratory Syncytial Virus Infection During Infancy

Area of Science:

• Immunology
• Virology
• Pediatrics

Background:

• Respiratory syncytial virus (RSV) is a leading cause of infant hospitalization globally.
• Understanding mucosal immune responses in children is critical for developing effective vaccines.
• Age-related differences in immune capabilities may impact protection against RSV.

Purpose of the Study:

• To investigate the role of interferon alpha (IFN-α) in modulating mucosal immunity against RSV in a neonatal mouse model.
• To determine if IFN-α can overcome age-related deficits in IgA production following RSV infection.
• To explore the impact of IFN-α on B-cell activating factor (BAFF) expression in the nasal mucosa.

Main Methods:

• Neonatal and adult mice were infected with RSV.
• A subset of neonatal mice received intranasal IFN-α prior to RSV infection.
• Flow cytometry was used to measure B cells, BAFF, and IgA.
• RSV-specific IgA was quantified in nasal washes.
• Immunohistochemistry was performed on nasal-associated lymphoid tissue (NALT) and lungs for BAFF and IgA.

Main Results:

• IFN-α demonstrated a dual role as an antiviral and immune modulator in the RSV mouse model.
• Intranasal IFN-α administration in neonatal mice increased RSV-specific IgA production in the nasal mucosa.
• IFN-α treatment induced BAFF expression in the NALT of neonatal mice infected with RSV.
• Age-related differences in IgA production upon RSV infection were ameliorated by IFN-α administration.

Conclusions:

• IFN-α administration can enhance protective mucosal immunity against RSV in neonates.
• IFN-α may overcome age-dependent limitations in IgA responses to RSV.
• Targeting mucosal immunity with agents like IFN-α could be a strategy for preventing severe RSV disease in infants.